SecSonar.com

Pharming Group N.V. (PHAR)

Pharming Group N.V. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Pharming Group N.V. (PHAR) is a Biotechnology company based in NL with a market capitalization of $942.8M. Revenue grew 26.9% year-over-year and the company generated $49.3M in free cash flow. This page tracks PHAR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

NL · 404 employees · IPO Dec 23, 2020

Valuation

Valuation & price

$12.92 · as of May 17, 2026 · -39.0% vs 52w high

322.3

P/E ratio

Latest-FY diluted EPS

3.40

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$20.59$15.22$9.86Jul 25Dec 25Jun 26Jul 7, 25$9.88Jul 9, 25$10.01Jul 11, 25$10.00Jul 15, 25$10.11Jul 17, 25$10.31Jul 21, 25$10.23Jul 23, 25$10.10Jul 25, 25$10.26Jul 29, 25$9.86Jul 31, 25$11.11Aug 4, 25$12.25Aug 6, 25$12.29Aug 8, 25$13.23Aug 12, 25$11.30Aug 14, 25$11.38Aug 19, 25$12.58Aug 21, 25$12.66Aug 25, 25$14.28Aug 27, 25$13.97Aug 29, 25$14.90Sep 3, 25$14.36Sep 5, 25$15.26Sep 9, 25$14.87Sep 11, 25$14.80Sep 15, 25$13.89Sep 17, 25$14.60Sep 19, 25$14.88Sep 23, 25$14.77Sep 25, 25$14.80Sep 29, 25$14.18Oct 2, 25$15.23Oct 6, 25$15.38Oct 8, 25$14.37Oct 10, 25$14.27Oct 14, 25$14.55Oct 16, 25$14.38Oct 20, 25$14.21Oct 22, 25$13.10Oct 24, 25$13.60Oct 28, 25$13.76Oct 30, 25$13.14Nov 3, 25$13.32Nov 5, 25$13.18Nov 7, 25$15.43Nov 11, 25$15.79Nov 14, 25$16.81Nov 18, 25$15.91Nov 20, 25$16.25Nov 24, 25$17.12Nov 26, 25$17.75Dec 1, 25$16.23Dec 3, 25$15.81Dec 5, 25$16.75Dec 9, 25$17.01Dec 11, 25$17.73Dec 15, 25$16.28Dec 17, 25$16.61Dec 19, 25$16.62Dec 23, 25$17.24Dec 26, 25$17.80Dec 31, 25$17.67Jan 5, 26$16.81Jan 7, 26$17.18Jan 9, 26$18.71Jan 13, 26$18.02Jan 15, 26$18.16Jan 20, 26$17.92Jan 22, 26$19.93Jan 26, 26$20.40Jan 28, 26$20.59Jan 30, 26$20.47Feb 3, 26$17.26Feb 5, 26$16.04Feb 9, 26$16.37Feb 11, 26$15.57Feb 17, 26$16.30Feb 19, 26$16.47Feb 23, 26$16.76Feb 25, 26$16.80Feb 27, 26$16.30Mar 3, 26$15.40Mar 5, 26$15.83Mar 9, 26$15.99Mar 11, 26$15.88Mar 13, 26$14.51Mar 17, 26$15.49Mar 19, 26$15.47Mar 23, 26$16.01Mar 25, 26$16.23Mar 27, 26$16.31Apr 1, 26$16.92Apr 6, 26$16.50Apr 8, 26$16.98Apr 10, 26$17.09Apr 14, 26$17.68Apr 16, 26$17.33Apr 20, 26$17.57Apr 22, 26$17.08Apr 24, 26$16.68Apr 28, 26$16.42Apr 30, 26$16.53May 4, 26$16.39May 6, 26$16.40May 8, 26$12.98May 12, 26$13.09May 15, 26$12.92May 19, 26$12.60May 21, 26$12.81May 26, 26$13.62May 28, 26$13.66Jun 1, 26$13.10Jun 3, 26$12.24Jun 5, 26$12.54Jun 9, 26$12.59Jun 11, 26$12.88Jun 15, 26$12.82Jun 17, 26$12.65Jun 22, 26$12.71Jun 24, 26$12.98Jun 30, 26$13.90
$9.8052-week range$21.18
Loading valuation history…

Fundamentals

Key fundamentals

$942.8M

Market cap

26.9%

Revenue growth (YoY)

87.9%

Gross margin

$49.3M

Free cash flow (USD)

-$64M

Net debt

Net cash position

3.5%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$16.7MFY 2017$107.5MFY 2018$154.6MFY 2019$189.4MFY 2020$212.2MFY 2021$198.9MFY 2022$205.6MFY 2023$245.3MFY 2024$297.2MFY 2025$377.2M
$16.7M$377.2M

Free cash flow by year

2016 → 2025

FY 2016$-12.1MFY 2017$38.6MFY 2018$41.9MFY 2019$48.7MFY 2020$68.3MFY 2021$21.1MFY 2022$20.5MFY 2023$-18.8MFY 2024$-2.6MFY 2025$49.3M
-$12.1M$49.3M

Gross margin by year

2021 → 2025

FY 202189.4%FY 202291.5%FY 202389.7%FY 202488.1%FY 202587.9%
89.4%87.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed May 28, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingFDA Acceptance AnnouncementJun 4, 2026Filing
  • Annual reportAnnual Report FiledMay 28, 2026Filing
  • 6-K filingMarketing Authorization GrantedMay 22, 2026Filing
  • Annual reportAnnual Report FiledMay 7, 2026Filing
  • 6-K filingPresentations at CIS 2026May 7, 2026Filing
  • 6-K filingAnnual General Meeting AnnouncementApr 16, 2026Filing
  • Annual report20-F FiledApr 13, 2026Filing
  • Annual reportAnnual Report FiledApr 2, 2026Filing
  • Annual report20-F FiledApr 2, 2026Filing

Questions

Frequently asked questions

What is Pharming Group N.V.'s market cap?

Pharming Group N.V. (PHAR) has a market capitalization of $942.8M.

What is PHAR's P/E ratio?

PHAR trades at a price-to-earnings ratio of 322.3, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is PHAR's price-to-book (P/B) ratio?

PHAR trades at 3.40 times book value per share.

Are insiders buying PHAR stock?

SEC Form 4 filings show no open-market insider buys at Pharming Group N.V. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

MGTX

MeiraGTx Holdings plc

$962.2M

ABUS

Arbutus Biopharma Corporation

$922.5M

LXRX

Lexicon Pharmaceuticals, Inc.

$975M

SPRY

ARS Pharmaceuticals, Inc.

$908.6M

KURA

Kura Oncology, Inc.

$900.2M

JANX

Janux Therapeutics, Inc.

$894.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.